TScan Therapeutics (NASDAQ:TCRX) Receives Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $15.00 target price on shares of TScan Therapeutics in a research report on Thursday, March 7th.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $7.26 on Tuesday. The firm has a market capitalization of $347.61 million, a PE ratio of -3.84 and a beta of 0.90. The stock’s fifty day moving average is $7.11 and its 200 day moving average is $5.77. TScan Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $9.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings results on Wednesday, March 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. The company had revenue of $7.21 million during the quarter, compared to the consensus estimate of $2.94 million. TScan Therapeutics had a negative return on equity of 60.65% and a negative net margin of 423.86%. On average, sell-side analysts anticipate that TScan Therapeutics will post -1.03 earnings per share for the current year.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors have recently made changes to their positions in TCRX. abrdn plc purchased a new position in shares of TScan Therapeutics during the fourth quarter valued at $1,166,000. Letko Brosseau & Associates Inc. purchased a new position in shares of TScan Therapeutics during the third quarter valued at $83,000. Cannon Global Investment Management LLC purchased a new position in shares of TScan Therapeutics during the first quarter valued at $139,000. Finally, Pale Fire Capital SE purchased a new position in shares of TScan Therapeutics during the third quarter valued at $42,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.